ABSTRACT
Background Despite safe and effective vaccines to prevent Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and disease, a substantial minority of the US remains resistant to getting vaccinated. It is imperative to know if expanding vaccination rates could reduce community-wide Coronavirus 2019 (COVID-19) disease, not just among those vaccinated.
Methods Negative binomial models were used to estimate associations between U.S. county-level vaccination rates and county-wide COVID-19 incidence and mortality between April 23rd and September 30th, 2021. A two-week lag and a four-week lag were introduced to assess vaccination rate impact on incidence and mortality, respectively. Stratified analyses were performed for county vaccination rates 40%, and before and after Delta became the dominant variant.
Findings Among 3,070 counties, each percentage increase in population vaccination rates reduced county-wide COVID-19 incidence by 0·9% (relative risk (RR) 0. 9910 (95% CI: 0·9869, 0·9952)) and mortality by 1·9% (RR 0·9807 (95% CI: 0·9745, 0·9823)). Among counties with vaccination coverage >40%, each percentage increase in vaccination rates reduced COVID-19 disease by 1·5%, RR 0·9850 (95% CI: 0·9793, 0·9952) and mortality by 2·7% (RR 0·9727 (95% CI: 0·9632, 0·9823)). These associations were not observed among counties with <40% vaccination rates. Increasing vaccination rates from 40% to 80% would have reduced COVID-19 cases by 45·4% (RR 0·5458 (95% CI: 0·4335, 0·6873)) and deaths by 67·0% (RR 0·3305 (95% CI: 0·2230, 0·4898)). An estimated 5,989,952 COVID-19 cases could have been prevented and 127,596 lives saved had US population vaccination rates increased from 40% to 80%.
Interpretations Increasing U.S. SARS-CoV-2 vaccination rates results in population-wide reductions in COVID-19 incidence and mortality. Furthermore, increasing vaccination rates above 40% has protective effects among non-vaccinated persons. Given ongoing vaccine hesitancy in the U.S., increasing vaccination rates could better protect the entire community and potentially reach herd immunity.
Funding National Cancer Institute
Competing Interest Statement
F Fang and TF Brewer held stock in Pfizer. All other authors declare no competing interests.
Funding Statement
NIH/NCI T32 CA009142
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Johns Hopkins University Center for Systems Science and Engineering Coronavirus Resource Center (CSSE, https://github.com/CSSEGISandData/COVID-19/blob/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_US.csv) Covid Act Now (https://apidocs.covidactnow.org/data-definitions/#vaccinations) GitHub repository (https://github.com/wxwx1993/PM_COVID) The US Census/American Community Survey The County Health Rankings & Roadmaps program (https://www.countyhealthrankings.org/explore-health-rankings/rankings-data-documentation) ArcGIS hub (https://hub.arcgis.com/datasets/geoplatform::hospitals/about) Economic Research Service (https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/) Boston University of Public Health (https://docs.google.com/spreadsheets/d/1zu9qEWI8PsOI_i8nI_S29HDGHlIp2lfVMsGxpQ5tvAQ/edit#gid=97365544)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
